Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020475 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020475: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00020475 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020475, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.
Interventions
- DRUG Montanide ISA-51
- DRUG gp100 antigen
- DRUG MART-1 antigen
- DRUG interleukin-2
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00020475 record still lists
NCT00020475 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which Montanide ISA-51 is the first listed.
NCT00020475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020475 about?
NCT00020475 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating ...
What is the current status of trial NCT00020475?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00020475?
The interventions under investigation include: Montanide ISA-51 (DRUG), gp100 antigen (DRUG), MART-1 antigen (DRUG), interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00020475?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia